A Mount Sinai-led research team has identified stem cell populations and mechanisms underlying age-related degeneration in meibomian glands, which secrete lipid-rich meibum to prevent tear evaporation. The findings suggest that targeting Hh and EGFR signaling could be a potential therapeutic option for evaporative dry eye disease.
Researchers developed reprogrammed vascular endothelial cells that provide strong support for islets, allowing them to survive and reverse diabetes long-term. The study showed that mice transplanted with islet cells plus R-VECs regained normal blood glucose control after 20 weeks.
Dr. Paola Arlotta's groundbreaking research on stem cell-derived brain organoids has redefined human brain development and neurological disease understanding. Her work provides access to the complexities of developing human brains, making her a deserving recipient of the ISSCR Momentum Award.
Researchers discover that the gene HMGA1 'opens' regions of the genome to activate stem cell genes, leading to tumor development and progression. High levels of HMGA1 also allow mutant tumor cells to escape detection by immune cells.
Dr. Gordon Keller's groundbreaking research on directed differentiation of human pluripotent stem cells has illuminated the path to transforming human health. His lab's world-first discovery and pioneering efforts have pushed the boundaries of what is possible, offering hope for regenerating heart, liver, and blood cells.
Researchers discovered a novel mechanism of intercellular communication through mRNA transfer between stem cells, allowing for biologically significant effects such as cell fate conversion and pluripotent state maintenance.
Researchers will present findings on Treatment Outcomes By Duffy Genotype in Patients with Newly Diagnosed Multiple Myeloma, highlighting longer progression-free survival for those receiving Lenalidomide, Bortezomib, and Dexamethasone alone or with autologous stem cell transplantation. Another study found that immune reactions leading ...
A new case report reveals a rare and aggressive form of leukemia developing from donor cells nine years after a stem cell transplant. The disease, driven by genetic mutations in key genes, progresses despite intensive treatment and ultimately proves fatal.
Researchers at Fujita Health University have developed a novel therapy using mesenchymal stem cells to treat inflammatory eye diseases, reducing inflammation and promoting tissue repair. The study found that adMSC injections effectively reduced inflammation in mice with GVHD without long-term complications.
The ISSCR International Symposium will commemorate the 20th anniversary of iPSC discovery, highlighting breakthrough achievements and new research advances. The event aims to celebrate the transformative power of scientific curiosity and its potential to unlock cures for previously untreatable diseases.
A University of Ottawa neuroscientist has led a Canadian research team to discover how neural stem cells integrate signals from different cell types and decode them. The study found that low daughter cell numbers trigger activation, while high numbers keep them in quiescence, offering new insights into cellular relationships and potent...
A KAIST research team identified core gene expression networks regulated by proteins that drive phenomena such as cancer development and tissue differentiation. The study revealed that IPMK acts as a critical transcriptional activator in these networks, enhancing SRF's protein activity.
Researchers have developed a novel stem cell treatment strategy for leptomeningeal brain metastasis, a severe form of metastatic brain cancer. The new therapy, which combines allogeneic dual stem cells with oncolytic herpes simplex virus and single chain variable fragment of anti-PD-1, shows promise in preclinical models.
Researchers analyzed 101 Chinese AML samples and identified three subtypes with different molecular characteristics and clinical outcomes. The study also found potential drug combinations that could improve treatment efficacy for subtype S-II&III patients who benefited from allogenic haematopoietic stem cell transplantation.
Researchers at Gladstone Institutes have shown that modified stem cells can improve brain activity after a stroke, even when administered one month later. The treatment reversed brain hyperexcitability and restored balance in neural networks, leading to long-lasting effects on brain function and repair.
A preclinical study by Weill Cornell Medicine investigators found that an immune protein called the inflammasome helps prevent blood stem cells from becoming malignant by removing certain receptors and blocking cancer gene activity. The study suggests that targeting the earliest stages of cancer may lead to new therapies.
Researchers at UCSF have discovered a new type of stem cell in the young brain that can form cells found in tumors, shedding light on how adult brain cells grow and develop into deadly brain cancers. The study provides a comprehensive roadmap for understanding healthy brain development, which could lead to better treatments for conditi...
Researchers from Korea University have developed a groundbreaking technique to transform fibroblasts into mature cardiomyocytes, holding promise for regenerative medicine in treating cardiovascular disease. The method combines fibroblast growth factor 4 (FGF4) with vitamin C to accelerate cell maturation and enhance function.
A Phase I clinical trial demonstrated long-term safety and feasibility of neural stem cell transplantation for treating chronic spinal cord injuries. Two patients showed durable evidence of neurological improvement with increased motor and sensory scores.
Researchers have successfully transplanted stem cells from resilient individuals into sea anemones, which are closely related to corals, demonstrating the feasibility of this approach. This innovative method could potentially lead to a new way to revive and restore coral populations damaged by climate change.
A preclinical study suggests the experimental compound K884 can restore lost muscle function in Duchenne muscular dystrophy (DMD) patients by strengthening muscle repair. The drug targets specific enzymes, allowing muscle stem cells to develop into functional tissue.
Dr. Christopher Seet has received a $2.9 million R37 MERIT Award from the National Cancer Institute to develop innovative T cell therapies for cancer. The grant will support research into iPSC-derived T cells, which can be engineered for enhanced tumor-fighting capabilities.
A Phase I clinical trial found that patients receiving itacitinib before and after a 'half-match' stem cell transplant experienced lower-than-expected rates of graft-versus-host disease, with no severe cases reported. The study also showed improved overall survival at one year, with 80% of patients remaining free from chronic graft-ver...
Mesenchymal stem cells (MSCs) show promise in delivering treatments directly to cancer cells and boosting the immune system's fight against cancer. However, ongoing research highlights challenges related to MSC behavior, including variability in their effects and potential to create conditions that support tumor growth.
Researchers at Medical University of South Carolina and University of Florida developed a novel approach to treat type 1 diabetes using tagged beta cell transplant with localized immune protection. The study, published in Cell Reports, shows promise for creating an off-the-shelf solution for T1D treatment.
Researchers from Kyushu University have developed an antibody that targets and prevents the dysfunction of hepatocyte growth factor (HGF), a critical protein for skeletal muscle development, regeneration, and repair. The new antibody, 1H42F4N, blocked nitration of HGF and did not disrupt its activity.
The new hospital will provide patient-centered care with personalized, compassionate treatment and groundbreaking research. Patients will have access to top specialists and pioneering therapies in cancer treatment.
The ISSCR has developed a comprehensive Continuing Education (CE) course on stem cell-based therapies, covering fundamental biology, clinical trials, and patient communication. The open-access course aims to equip healthcare providers with accurate information, empowering them to navigate the complexities of this evolving field.
A team of researchers at the University of Toronto has discovered two distinct subtypes of glioblastoma cancer stem cells, each with unique genetic vulnerabilities. By targeting these vulnerabilities, a more effective treatment approach may be developed, improving prognosis for patients with this lethal brain cancer.
Researchers at MD Anderson Cancer Center have made significant advancements in understanding tissue regeneration, with a focus on epigenetic regulation and retrotransposon suppression. MicroRNAs have also been identified as potential biomarkers for COVID-19 severity in cancer patients, while a novel protein complex drives lung regenera...
Researchers used ex vivo lentiviral gene therapy to treat MPS IVA in mice, achieving partial correction of bone pathology and complete correction of heart pathology. The study suggests potential for novel therapies to treat patients with MPS IVA.
A team of bioethicists and legal scholars call for clear and concise regulations on exosome-based treatments due to the lack of scientific evidence and existing regulatory frameworks. These unproven interventions can cause serious harm to patients, highlighting the need for stronger protections.
Researchers at Kumamoto University have achieved a groundbreaking advancement in stem cell biology by reproducing the developmental process of hematopoietic stem cells in vitro. This culture system enhances our understanding of HSC development and has the potential to be instrumental in stem cell therapy and blood disease treatments.
Researchers found Edaravone inhibits growth of brain tumor stem cells and prolongs survival in mice with glioblastoma. The study suggests repurposing Edaravone as a potential treatment for this aggressive brain cancer.
Glioblastoma, the most malignant primary brain tumour, has an 18-month median survival rate despite treatment. New research from the University of Ottawa suggests a drug used to slow ALS progression may also suppress glioblastoma's self-renewing cancerous stem cells.
TP53 mutations are commonly associated with therapy-related AML and complex cytogenetics. Researchers found improved long-term outcomes when allo-HCT was performed during Complete Remission 1 (CR1), despite limited effective therapies for TP53-mutated AML.
Researchers have successfully transplanted human embryonic stem cell-derived retinal organoid sheets into monkeys with macular holes, resulting in graft survival and maturation of light-detecting cells. The study suggests that this method could become a practical treatment option for difficult macular hole cases.
Researchers at Osaka Metropolitan University have successfully generated high-quality feline induced pluripotent stem cells (iPSCs) without a genetic footprint. These cells exhibit properties similar to human iPSCs and can differentiate into various cell types, making them a promising tool for veterinary regenerative medicine research.
Melbourne researchers have developed a breakthrough in creating lab-grown human blood stem cells, which can be used to treat childhood blood disorders. The cells closely mimic those found in the human embryo and can create specific matched blood cells for transplantation, reducing complications and addressing donor shortages.
Researchers led by Prof. Michael Brand successfully regenerated photoreceptors in zebrafish, demonstrating they regain their normal function and allowing the fish to recover complete vision. This breakthrough could potentially revolutionize treatment of diseases like retinitis pigmentosa or macular degeneration.
Researchers discovered that blocking Cxcr4 in mice reduced white fat tissue, while estrogen therapy could be effective with lower doses. The study offers promising avenues for understanding healthy and unhealthy fat tissue development.
Texas A&M researchers are investigating the use of extracellular vesicles to deliver immune-suppressing proteins, potentially reducing the immune system's attack on insulin-producing beta-cells. The goal is to develop a novel treatment for type 1 diabetes, which currently has only lifelong insulin therapy as an approved option.
A new technique developed by McGill researchers allows for precise targeting of stem cells to become specific cell types, such as bone or fat cells. This breakthrough has the potential to lead to new stem cell treatments for various diseases, including multiple sclerosis, Alzheimer’s and Type 1 diabetes.
Researchers at the Centre for Genomic Regulation have discovered a treatment that speeds up the production of high-quality pluripotent stem cells in mice. The finding uses interferon gamma to accelerate cellular reprogramming, paving the way for improved disease modeling and personalized treatments.
A UofL cardiologist is leading a Phase II clinical trial of a new stem cell therapy for heart failure, the first in the US to use intravenous delivery. The trial aims to determine whether one or multiple doses of mesenchymal stem cells improve health and quality of life for patients.
Researchers at the University of Helsinki have created cells that can't grow uncontrolledly, which could lead to new and safer cell therapies for hereditary diseases, myocardial infarction, and other conditions. The innovation uses thymidine supplementation to regulate cell division, eliminating the risk of cancer.
Researchers identified genetic and metabolic characteristics of leukaemic stem cells, including a specific iron utilisation process that can be blocked to kill these cells without harming healthy ones. This breakthrough paves the way for new therapeutic strategies to combat leukemia.
Researchers found that autologous bone marrow aspirate concentrate (BMAC) and adipose-derived stromal vascular fraction (ADSVF) have distinct cellular compositions and protein profiles. The study's findings challenge the marketing of these therapies as interchangeable and highlight the need for standardized cell therapies.
Researchers at University of California San Diego have found that genetically modified NK-cell therapy can effectively target and treat hepatocellular carcinoma, a highly treatment-resistant form of solid tumor. The therapy works by disabling the inhibitory protein TGF-β, allowing immune cells to kill cancer more efficiently.
Researchers at UCSF have discovered a way to turn ordinary white fat cells into beige fat cells that burn calories, opening the door to developing new weight-loss drugs. The approach uses a protein called KLF-15 and may avoid side effects associated with current treatments.
A new study demonstrates the potential of stem cell therapy to treat Hirschsprung disease by generating nerve cell precursors that produce missing nerves in the intestine. Transplanted gut samples showed improved functionality, suggesting a breakthrough for this rare condition.
Researchers at Texas A&M University have discovered a new technique for tissue regeneration using mineral-based nanomaterials inspired by ancient medical practices. The approach aims to induce natural bone formation, reducing the need for invasive procedures and long-term medication, and promoting improved quality of life.
Research led by Weill Cornell Medicine found that most colorectal cancers begin with the loss of intestinal stem cells, even before cancer-causing genetic alterations appear. This new understanding suggests a unified model for colorectal cancer initiation where damage to intestinal crypts causes a decrease in aPKC protein expression.
Researchers explore nanoparticle-based therapies to specifically target lymphatic metastasis in breast cancer, providing a promising solution for patient treatment. Nanoparticles deliver drugs directly to tumors, targeting cancer cells to destroy them or slow their growth, while also enhancing the immune response.
Researchers have developed an approach to 'delete' a diseased blood system while building up a new, healthy one with donor blood stem cells. This process involves targeting specific antibodies coupled to a cytotoxic drug that recognize and destroy diseased blood cells while sparing healthy ones.
Researchers review cell-based therapies for comprehensive sepsis management, highlighting the potential of mesenchymal stem cells and innate immune cells like macrophages. The review also emphasizes the need for further studies on optimal dosage, administration routes, and storage methods to maximize efficacy and safety.
Researchers at UMSOM identified a modified sugar molecule that enhances human neural stem cells' proliferation and transition into neurons, improving brain function and reducing anxiety and depression. The study provides a promising proof of concept for regenerative medicine in patients with cardiac-arrest induced brain injuries.
Researchers at KTH Royal Institute of Technology have developed a microfluidic device that converts skin cells into neural stem cells, speeding up the process and reducing costs. This advance brings personalized cell-based therapies for Alzheimer's and Parkinson's closer to reality.
A recent study published in Nature Cell Biology found that increased hydrostatic pressure can hinder the healthy development of neural crest cells, leading to an increased risk of facial malformations. The researchers suggest that physical cues in the womb, such as pressure, may play a role in shaping facial features.
Researchers discovered MIA-602's effectiveness against Doxorubicin-resistant acute myeloid leukemia (AML), demonstrating reduced cell viability and tumor volume. The study suggests MIA-602 as a potential alternative treatment approach for AML, potentially circumventing chemotherapy side effects.